On March 31, 2025, GT Biopharma issued a pre-funded warrant to Cytovance Biologics for 326,251 shares of common stock at an exercise price of $0.0001 per share, in exchange for services valued at $846,562.50. Effective July 1, 2024, the company will operate fully remote without a principal executive office.